The overall goal of the Clinical Oncology Research Career Development Program is to support the intent of the Paul Calabresi Award for Clinical Oncology (K12). The Program fosters interdisciplinary training in clinical and translational oncology therapeutic research for physicians in one of a number of oncology disciplines, including medical, surgical, dermatologic, pediatric, radiation and pathology. By designing a K12 program that brings together these broad disciplines, the Paul Calabresi Scholars themselves form a multidisciplinary group whose collaborations and interactions augment the overall training efforts under the K12 program. Firm core requirements include completion of required and elective course work for a Certificate in Clinical Translational Oncology at CWRU. A basic research effort is a required part of the training program and is linked to the clinical research efforts that include writing and activating a therapeutic clinical protocol and submission of a career development award application. These efforts will result in highly qualified Paul Calabresi scholars capable of independent research in clinical oncology and therapeutics with a team science orientation based in hypothesis testing of important translational questions in the field. The Program brings together strong Internal and External Advisory Committees committed and experienced in the area of clinical translational therapeutics research in oncology. The Program and the cancer center provides scholars with an outstanding environment to pursue career development. Past trainees have emerged as academic physicians developing independent clinical research programs often with external funding and with active investigator-initiated clinical trial efforts.
This mentored career development program supports physician investigators to gain skills in cancer research and clinical therapeutics that emphasizes innovative treatments and use of genomics to select proper and individualized treatments for cancer patients, increasing the likelihood that such treatment will be effective.
|Eads, Jennifer R; Beumer, Jan H; Negrea, Lavinia et al. (2016) A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemother Pharmacol 77:333-8|
|Gutierrez, Daniel; Arbesman, Joshua (2016) Circadian Dysrhythmias, Physiological Aberrations, and the Link to Skin Cancer. Int J Mol Sci 17:|
|de Blank, Peter M K; Fisher, Michael J; Lu, Lu et al. (2016) Impact of vision loss among survivors of childhood central nervous system astroglial tumors. Cancer 122:730-9|
|Metheny 3rd, Leland; Eid, Saada; Lingas, Karen et al. (2016) Intra-osseous Co-transplantation of CD34-selected Umbilical Cord Blood and Mesenchymal Stromal Cells. Hematol Med Oncol 1:25-29|
|Gollamudi, Jahnavi; Parvani, Jenny G; Schiemann, William P et al. (2016) Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Manag Res 8:21-31|
|Gittleman, Haley R; Ostrom, Quinn T; Rouse, Chaturia D et al. (2015) Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121:102-12|
|Telli, Melinda L; Jensen, Kristin C; Vinayak, Shaveta et al. (2015) Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol 33:1895-901|
|de Blank, Peter M; Ostrom, Quinn T; Rouse, Chaturia et al. (2015) Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. Cancer Med 4:608-19|
|Peiris, Pubudu M; Abramowski, Aaron; Mcginnity, James et al. (2015) Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Res 75:1356-65|
|Goebel, Teresa E; Schiltz, Nicholas K; Woodside, Kenneth J et al. (2015) Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance. Clin Transplant 29:851-7|
Showing the most recent 10 out of 49 publications